Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 13/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL322981 | 0.74 | HSD11B1 (0.42) | HSD11B1TSHRPTGS1PTGS2ALDH1A1 | |
| SCHEMBL1500290 | 0.74 | TSHR (0.58) | HSD11B1TSHRPTGS1PTGS2ALDH1A1 | |
| SCHEMBL6600300 | 0.74 | HSD11B1 (0.42) | HSD11B1TSHRPTGS1PTGS2ALDH1A1 | |
| SCHEMBL322982 | 0.74 | HSD11B1 (0.42) | HSD11B1TSHRPTGS1PTGS2ALDH1A1 | |
| SCHEMBL544019 | 0.74 | SMN1; SMN2 (0.50) | HSD11B1TSHRALDH1A1 | |
| SCHEMBL3562652 | 0.74 | ALDH1A1 (0.43) | HSD11B1TSHRPTGS1PTGS2ALDH1A1 | |
| SCHEMBL15875128 | 0.74 | KDM4E (0.49) | HSD11B1TSHRGAAPTGS1PTGS2 | |
| SCHEMBL2077909 | 0.74 | ALDH1A1 (0.51) | HSD11B1GAAALDH1A1 | |
| SCHEMBL13509856 | 0.74 | HSD11B1 (0.58) | HSD11B1ALDH1A1 | |
| SCHEMBL1395472 | 0.72 | TSHR (0.70) | TSHRPTGS1PTGS2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-11171870-A | — | — | None | — | — | JP | disclosed |
| US-20230295220-A1 | C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2023-09-21 | — | — | US | disclosed |
| EP-3831839-B1 | C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2023-07-26 | — | — | EP | disclosed |
| US-20210323997-A1 | C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS | VIIV Healthcare UK (No.5) Limited (GB) | 2021-10-21 | — | — | US | disclosed |
| US-11084845-B2 | C-3 and C-17 modified triterpenoids as HIV-1 inhibitors | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2021-08-10 | — | — | US | disclosed |
| EP-3831839-A2 | C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS | ViiV Healthcare UK (No.5) Limited (GB) | 2021-06-09 | — | — | EP | disclosed |
| CN-109153700-B | C-3 and C-17 modified triterpenoids as HIV-1 inhibitors | VIIV保健英国第五有限公司 | 2021-03-09 | — | — | CN | disclosed |
| EP-3411381-B1 | C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2021-01-20 | — | — | EP | disclosed |
| US-10421774-B2 | C-3 and C-17 modified triterpenoids as HIV-1 inhibitors | VIIV Healthcare UK (No.5) Limited (GB) | 2019-09-24 | — | — | US | disclosed |
| US-20190031709-A1 | C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2019-01-31 | — | — | US | disclosed |
| EP-1850178-A2 | Dye-containing negative curable composition, color filter and method for producing the same | FUJIFILM Corporation (JP) | 2007-10-31 | — | — | EP | disclosed |
| EP-0545301-B1 | Silver halide color photographic light-sensitive material | FUJI PHOTO FILM CO LTD (JP) | 2000-03-01 | — | — | EP | disclosed |
| JP-H11171870-A | NEW OXONOLS | FUJI PHOTO FILM CO LTD | 1999-06-29 | — | — | JP | disclosed |
| US-5827637-A | INCLUDING A METAL COORDINATION COMPOUND HAVING PHOTOGRAPHICALLY USEFUL GROUP(S) BONDED THROUGH BLOCK GROUP TO MULTIDENTATE LIGAND(S) WHEREBY USEFUL GROUP IS CLEAVED UPON CLEAVAGE OF METAL DURING PHOTOGRAPHIC PROCESSING | FUJI PHOTO FILM CO., LTD. (JP) | 1998-10-27 | — | — | US | disclosed |
| US-5342742-A | Silver halide color photographic light-sensitive material comprising a pyrrolotriazole cyan coupler and a specific yellow coupler | FUJI PHOTO FILM CO., LTD. (JP) | 1994-08-30 | — | — | US | disclosed |
| EP-0545301-A1 | Silver halide color photographic light-sensitive material | FUJI PHOTO FILM CO., LTD. (JP) | 1993-06-09 | — | — | EP | disclosed |
| US-5063148-A | Bicyclic pyrazole magenta couplers and a diphenol-type stabilizer provide improved colorfastness and reproduction; free from yellow stains | KONICA CORPORATION (JP) | 1991-11-05 | — | — | US | disclosed |
| US-5024930-A | Forming images fast to heat, moisture, light | KONICA CORPORATION (JP) | 1991-06-18 | — | — | US | disclosed |
| EP-0398664-A2 | A silver halide photographic light-sensitive material containing a novel photographic coupler | KONICA CORPORATION (JP) | 1990-11-22 | — | — | EP | disclosed |
| EP-0391341-A2 | Silver halide light-sensitive photographic material | KONICA CORPORATION (JP) | 1990-10-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10421774-B2 | C-3 and C-17 modified triterpenoids as HIV-1 inhibitors | IL17A, BET1, CD4 | HSD11B1 351/4885TSHR 4736/4885GAA 1067/4885 |
| US-11084845-B2 | C-3 and C-17 modified triterpenoids as HIV-1 inhibitors | IL17A, BET1, CD4 | HSD11B1 351/4885TSHR 4736/4885GAA 1067/4885 |
| US-20230295220-A1 | C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS | IL17A, BET1, CD4 | HSD11B1 351/4885TSHR 4736/4885GAA 1067/4885 |
| US-20190031709-A1 | C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS | IL17A, BET1, CD4 | HSD11B1 351/4885TSHR 4736/4885GAA 1067/4885 |
| US-20210323997-A1 | C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS | IL17A, BET1, CD4 | HSD11B1 351/4885TSHR 4736/4885GAA 1067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.